Work

Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors

Year: 2020

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-020-04176-z

Authors: Khanh T. Do, Geraldine O’Sullivan Coyne, John L. Hays, Jeffrey G. Supko, Stephen V. Liu, Kristin Beebe, Len Neckers, Jane B. Trepel, Min-Jung Lee, Tomoko Smyth, Courtney Gannon, Jennifer Hedglin, Alona Muzikansky, Susana Campos, John Lyons, Percy Ivy, James H. Doroshow, Alice P. Chen, Geoffrey I. Shapiro

Institutions: Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, National Cancer Institute, The Ohio State University Wexner Medical Center, Massachusetts General Hospital, Georgetown University Medical Center, Center for Cancer Research

Language: English

Topic: Heat shock proteins research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Gateway for Cancer Research, National Cancer Institute

Awards: G4001869557, G6347764857, G644256362

OpenAlex ID: W3094012184

FWCI: 0.774

Cites: 40

Cited by: 21

Related to: 10